One Capital Management LLC Increases Stock Holdings in Danaher Co. (NYSE:DHR)

One Capital Management LLC boosted its position in shares of Danaher Co. (NYSE:DHR) by 277.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,026 shares of the conglomerate’s stock after acquiring an additional 3,694 shares during the quarter. One Capital Management LLC’s holdings in Danaher were worth $1,256,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Cape Investment Advisory Inc. acquired a new stake in Danaher in the 4th quarter valued at about $25,000. Tsfg LLC raised its position in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher in the 2nd quarter valued at about $25,000. nVerses Capital LLC acquired a new stake in Danaher in the 2nd quarter valued at about $25,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in Danaher in the 1st quarter valued at about $30,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the topic of a number of analyst reports. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 target price on shares of Danaher in a research report on Friday, September 6th. Barclays raised their target price on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 24th. Bank of America raised their target price on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Finally, Evercore ISI cut their target price on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $278.94.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 over the last three months. 11.10% of the stock is currently owned by insiders.

Danaher Stock Up 0.7 %

Danaher stock opened at $276.06 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The company has a market cap of $199.37 billion, a PE ratio of 46.79, a price-to-earnings-growth ratio of 4.48 and a beta of 0.83. The stock’s 50 day moving average price is $265.25 and its 200 day moving average price is $256.67.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.05 earnings per share. On average, sell-side analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.